trending Market Intelligence /marketintelligence/en/news-insights/trending/g6vdaskbrgodlbt1fb1whq2 content esgSubNav
In This List

Deciphera appoints Agios executive to board

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Deciphera appoints Agios executive to board

Deciphera Pharmaceuticals, Inc. said it appointed Agios Pharmaceuticals Inc.'s chief commercial officer to its board.

The addition of Steven Hoerter to the Waltham, Mass.-based biopharmaceutical company's board increases its size to nine members from eight.

Deciphera expects Hoerter to assist the company as it advances its treatment, DCC-2618, for patients with gastrointestinal stromal tumors.

At Agios, Hoerter is responsible for the commercialization of the company's portfolio of medicines for oncology and rare genetic diseases.